Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Belluscura PLC ( (GB:BELL) ) has issued an update.
Belluscura PLC reported a significant increase in Q1 2025 sales to $912,000, up from $166,000 in Q1 2024. Despite facing a 20% tariff on products sold in the US due to new import duties on Chinese and Hong Kong goods, the company is exploring ways to mitigate these costs. The launch of the X-PLOR 5, a lightweight, FDA-cleared portable oxygen concentrator, has seen strong initial demand, and the DISCOV-R is expected to launch commercially in Q3 FY25. Additionally, the company announced the resignation of CFO Simon Neicheril, with Chairman Paul Tuson temporarily assuming financial responsibilities.
More about Belluscura PLC
Belluscura PLC is a leading medical device developer specializing in lightweight and portable oxygen enrichment technology. The company focuses on creating innovative solutions for oxygen therapy, with a market emphasis on portable oxygen concentrators.
YTD Price Performance: -91.89%
Average Trading Volume: 2,381,965
Technical Sentiment Signal: Buy
Current Market Cap: £3.01M
For a thorough assessment of BELL stock, go to TipRanks’ Stock Analysis page.